🚀 ProPicks AI Hits +34.9% Return!Read Now

Valeant ends relationship with Philidor

Published 2015-10-30, 06:03 a/m
© Reuters.  Valeant ends relationship with Philidor
PSON
-
BHC
-

Oct 30 (Reuters) - Valeant Pharmaceuticals (N:VRX) International
VRX.TO said it is terminating all ties with Philidor due to
allegations relating to the specialty pharmacy distributor's
business practices.
"We have lost confidence in Philidor's ability to continue
to operate in a manner that is acceptable to Valeant," Chief
Executive Michael Pearson (L:PSON) said. urn:newsml:reuters.com:*:nPn2XrdlQ
Earlier this week, Valeant said it would set up an ad hoc
committee to look into the allegations related to the company's
association with Philidor.
Influential short-seller Citron Research had accused the
drugmaker of using Philidor to create "phantom sales" of its
products or push more product through distribution channels than
sales would warrant, an allegation that Valeant has denied
outright. urn:newsml:reuters.com:*:nL1N12L19L
Valeant said it intends develop a plan to ensure patients'
access to drugs is minimally disrupted.
Valeant's link to Philidor and its option to buy the company
came under scrutiny after a New York Times report said Valeant
and other drugmakers were using specialty drug distributors to
circumvent barriers to raising prices.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.